Neil Littman

Chief Executive Officer

2024

Chief Business Officer

2023 - 2024

ReIGNITE is a biotechnology company using Directed Evolution to develop systemic high-capacity viral vector immunotherapies and gene therapies. Our unique platform leverages the Nobel Prize-winning technologies of Directed Evolution to develop customized high-capacity vectors with tissue-specific tropism.

Partner

2022

Investing in and nurturing the growth of next generation life science & healthcare companies. Through our flagship venture strategy, P9, we partner with and invest in management teams working on breakthrough biomedical technology at private companies, at all stages, from company formation to cross-over rounds. Driven by new advancements in precision medicine, we focus on companies developing therapeutics, devices, diagnostics, and data-driven insights that improve outcomes, expand access and lower overall costs. We have high conviction across our portfolio on both the scientific and clinical value propositions of our partners as well as the business and financial value propositions we are building towards.

Founder & General Partner

2016

Bioverge is a financial technology platform enabling investors - accredited, family offices, RIAs and institutions - to invest in the next generation of startups pushing the boundaries of healthcare to bring science fiction to life. We provide access to highly vetted healthcare startups and the opportunity to invest alongside us and other premier investors, at the same terms. Portfolio includes: Echo Laboratories (acquired), Volumetric (acquired), Blue Mesa Health (acquired), Circularis (acquired), IVIVA Medical (acquired), Alto Neuroscience (IPO), Enveda Biosciences, Octant Bio, Notable Labs, Octagon Therapeutics, HepaTx, EnClear Therapies, NutriSense, Contraline, and others. Learn more www.bioverge.com.

Vice President Of Business Development

2018 - 2020

Notable is a translational drug development platform built on a clinically validated approach to rapidly identify and advance blood cancer therapeutics at a fraction of traditional costs. Using cancer patient samples in a proprietary, physiologically-relevant ex vivo microenvironment, Notable’s automated flow cytometry laboratory can accurately predict the efficacy of new drugs, identify novel combinations, and stratify patients into subgroups — dramatically increasing a clinical trial’s probability of success.

Director, Business Development

2012 - 2018

With $3 billion AUM, the California Institute for Regenerative Medicine (CIRM) provides funding for the translation and clinical development of novel stem cell and regenerative medicine therapies. At CIRM, I was a member of the Executive Leadership Team with responsibilities for strategic collaborations, alliances, and partnerships with biopharma companies and investors. Previously managed CIRM's Therapeutics Team, which was responsible for > 45 clinical stage regenerative medicine therapies totaling >$500 million. Frequently invited speaker and panelist at scientific and business development conferences.

Healthcare Investment Banking, Senior Associate

2009 - 2012

Venture capital firm and boutique investment bank with >$1 billion AUM. Capital raising and investing experience includes both public and private financings (IPO, follow-on, registered direct, PIPE, and early stage venture deals).

Co-founder and Managing Partner

2007 - 2009

Hedge fund focused on derivatives trading utilizing a proprietary trading strategy and algorithm to arbitrage the volatility risk premium associated with equity index options.

Healthcare Investment Banking, Financial Analyst

2005 - 2007

Worked closely with C-level executives providing complex financial analysis, including M&A transactions and due diligence, forecasting, modeling, company valuations, competitive intelligence, and ROI analysis. Specialized in working with growth stage life sciences companies —from early stage startups raising $10M of capital to multi-billion dollar acquisitions.

Healthcare Investment Banking, Financial Analyst

2004 - 2005

Extensive experience conducting market research and valuation analysis for large and mid-sized domestic and international healthcare companies. Participated in deals worth $1 billion+.